Next Article in Journal
A Dose-Escalation Study Demonstrates the Safety and Tolerability of Cellobiose in Healthy Subjects
Previous Article in Journal
Urinary TMAO Levels Are Associated with the Taxonomic Composition of the Gut Microbiota and with the Choline TMA-Lyase Gene (cutC) Harbored by Enterobacteriaceae
Article

A Pilot Randomized Crossover Trial Assessing the Safety and Short-Term Effects of Walnut Consumption by Patients with Chronic Kidney Disease

1
Laboratory of Renal Lithiasis Research, University of Balearic Islands, Institute of Health Sciences Research [IUNICS-IdISBa], 07122 Palma of Mallorca, Spain
2
Nephrology Department, Hospital Son Llàtzer, Institute of Health Sciences Research [IUNICS-IdISBa], 07198 Palma of Mallorca, Spain
3
ALCER Illes Balears (Association for the Fight against Kidney Diseases, Balearic Islands), 07009 Palma, Spain
4
Laboratory Department, Hospital Son Llàtzer, 07198 Palma of Mallorca, Spain
*
Authors to whom correspondence should be addressed.
Nutrients 2020, 12(1), 63; https://doi.org/10.3390/nu12010063
Received: 1 November 2019 / Revised: 19 December 2019 / Accepted: 21 December 2019 / Published: 25 December 2019
The aim of this study of patients with chronic kidney disease (CKD) is to assess the safety of daily consumption of walnuts on the physiological levels of phosphorous, potassium, parathyroid hormone (PTH), and fibroblast growth factor 23 (FGF23), and to assess the short-term benefits of this intervention on risk factors associated with cardiovascular events. This led us to perform a prospective, randomized, crossover, pilot clinical trial examined 13 patients with CKD. Subjects were randomly assigned to a diet of 30 g of walnuts per day or the control diet. After 30 days, each group was given a 30-day washout period, and then switched to the alternate diet for 30 days. Urinary and serum levels of phosphorous and potassium, multiple vascular risk factors, and urinary inositol phosphates (InsPs) were measured at baseline and at the end of the intervention period. Our results showed that the walnut dietary supplement led to reduced blood pressure, LDL cholesterol, and albumin excretion, but had no effect on the physiological levels of phosphorous, potassium, PTH, and FGF23. This is the first report to show that daily consumption of walnuts by patients with CKD does not alter their physiological levels of phosphorous, potassium, PTH, and FGF23 when included in a sodium-, protein-, phosphate-, and potassium-controlled diet, and it could be an effective strategy for reducing cardiovascular risk in patients with CKD. View Full-Text
Keywords: walnuts; kidney disease; phytate; dietary intervention; phosphorous walnuts; kidney disease; phytate; dietary intervention; phosphorous
Show Figures

Figure 1

MDPI and ACS Style

Sanchis, P.; Molina, M.; Berga, F.; Muñoz, E.; Fortuny, R.; Costa-Bauzá, A.; Grases, F.; Buades, J.M. A Pilot Randomized Crossover Trial Assessing the Safety and Short-Term Effects of Walnut Consumption by Patients with Chronic Kidney Disease. Nutrients 2020, 12, 63. https://doi.org/10.3390/nu12010063

AMA Style

Sanchis P, Molina M, Berga F, Muñoz E, Fortuny R, Costa-Bauzá A, Grases F, Buades JM. A Pilot Randomized Crossover Trial Assessing the Safety and Short-Term Effects of Walnut Consumption by Patients with Chronic Kidney Disease. Nutrients. 2020; 12(1):63. https://doi.org/10.3390/nu12010063

Chicago/Turabian Style

Sanchis, Pilar, Marilisa Molina, Francisco Berga, Elena Muñoz, Regina Fortuny, Antonia Costa-Bauzá, Felix Grases, and Juan M. Buades. 2020. "A Pilot Randomized Crossover Trial Assessing the Safety and Short-Term Effects of Walnut Consumption by Patients with Chronic Kidney Disease" Nutrients 12, no. 1: 63. https://doi.org/10.3390/nu12010063

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop